AngioDynamics (ANGO) CEO Buys 10,000 Shares at $11.15

James C. Clemmer, President, CEO and a director of AngioDynamics, Inc. (ANGO), reported an insider purchase of common stock on 10/09/2025.

Rhea-AI Filing Summary

James C. Clemmer, President, CEO and a director of AngioDynamics, Inc. (ANGO), reported an insider purchase of common stock on 10/09/2025. The filing shows a purchase of 10,000 shares at a weighted average price of $11.15, with trade prices in the range $11.10 to $11.17. After the transaction the reporting person beneficially owns 882,529 shares.

The filing is a standard Section 16 Form 4 disclosing a direct purchase by the reporting person. The filer notes the purchase occurred in multiple transactions and offers to provide a breakdown of quantities by price on request. No derivative transactions or dispositions are reported.

Positive

• Insider purchase: CEO/director acquired 10,000 shares on 10/09/2025 at a weighted average price of $11.15
• Substantial ongoing ownership: Beneficial ownership increased to 882,529 shares, indicating continued insider stake

Negative

• None.

Insights

Corporate Insider / Governance Analyst

CEO made a modest open-market purchase, increasing direct holdings.

The report documents a direct acquisition of 10,000 common shares at a weighted average price of $11.15 on 10/09/2025

This purchase increases the CEO's beneficial ownership to 882,529 shares and was executed in multiple trades between $11.10 and $11.17. Monitor any future Form 4s for larger accumulations or sales within the next several weeks as confirmation of sustained buying or rebalancing.

Equity Market / Trading Analyst

Transaction size is small relative to total holdings; impact on float likely limited.

The bought amount (10,000 shares) is explicitly recorded as an open-market purchase with a weighted average price of $11.15. The filing contains no option exercises or disposals.

Because the filing states the trades were executed at prices from $11.10 to $11.17, short‑term market impact is likely minimal; traders may note insider buying but should weigh it against overall share count and liquidity in the days after 10/09/2025.

Insider Trade Summary

Net Buyer: 10,000 shares

Net Buy 1 txn

Insider Clemmer James C

Role President and CEO

Bought 10,000 shs ($112K)

Type	Security	Shares	Price	Value
Purchase	Common Stock	10,000	$11.15	$112K

Holdings After Transaction: Common Stock — 882,529 shares (Direct)

Footnotes (1)

1. F1. The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $11.10 to $11.17 inclusive. The reporting person has provided to AngioDynamics, Inc., and undertakes to provide to any security holder of AngioDynamics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote 1.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did AngioDynamics (ANGO) report on 10/09/2025?

The Form 4 reports that James C. Clemmer purchased 10,000 shares on 10/09/2025 at a weighted average price of $11.15.

How many AngioDynamics shares does the reporting person own after the purchase?

After the reported transaction the reporting person beneficially owns 882,529 shares.

Were the shares purchased at a single price or multiple prices?

The filing states the shares were bought in multiple transactions at prices ranging from $11.10 to $11.17, with a weighted average of $11.15.

Does the Form 4 report any derivative transactions or dispositions?

No. The filing shows a non-derivative acquisition only and does not list any derivative securities acquired or disposed of.

Who signed the Form 4 and when was it signed?

The Form 4 is signed by /s/ Lawrence T. Weiss, as Attorney in Fact and dated 10/09/2025.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 10/09/2025 - 09:09 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Clemmer James C

(Last) (First) (Middle)

14 PLAZA DRIVE

(Street)

LATHAM NY 12110

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
ANGIODYNAMICS INC [ ANGO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	President and CEO

3. Date of Earliest Transaction (Month/Day/Year)
10/09/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	10/09/2025		P		10,000	A	$11.15(1)	882,529	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $11.10 to $11.17 inclusive. The reporting person has provided to AngioDynamics, Inc., and undertakes to provide to any security holder of AngioDynamics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote 1.

	/s/ Lawrence T. Weiss, as Attorney in Fact	10/09/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.